Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer.
Adult
Aged
Aged, 80 and over
Area Under Curve
CA-19-9 Antigen
/ blood
Cell Line, Tumor
Exosomes
/ genetics
Female
Gene Expression Regulation, Neoplastic
Humans
Logistic Models
Male
Middle Aged
Multivariate Analysis
Pancreatic Neoplasms
/ blood
RNA, Messenger
/ genetics
RNA, Neoplasm
/ blood
ROC Curve
diagnostic marker
exosome
pancreatic cancer
small nucleolar RNA
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
01
08
2018
revised:
09
10
2018
accepted:
14
10
2018
pubmed:
26
10
2018
medline:
18
12
2019
entrez:
26
10
2018
Statut:
ppublish
Résumé
Diagnostic biomarkers for the early diagnosis of pancreatic cancer are needed to improve prognosis for this disease. The aim of this study was to investigate differences in the expression of four messenger RNAs (mRNAs: CCDC88A, ARF6, Vav3, and WASF2) and five small nucleolar RNAs (snoRNAs: SNORA14B, SNORA18, SNORA25, SNORA74A, and SNORD22) in serum of patients with pancreatic cancer and control participants for use in the diagnosis of pancreatic cancer. Results were compared with the expression of sialylated Lewis (a) blood group antigen CA19-9, the standard clinical tumor biomarker. Reverse transcription quantitative real-time PCR showed that all of the mRNAs and snoRNAs, except CCDC88A, were encapsulated in exosomes and secreted from cultured pancreatic cancer cells, and present in cell culture medium. In a discovery-stage clinical study involving 27 pancreatic cancer patients and 13 controls, the area under the receiver operating characteristic curve (AUC) of two mRNAs (WASF2 and ARF6) and two snoRNAs (SNORA74A and SNORA25) was > 0.9 for distinguishing pancreatic cancer patients from controls; the AUC of CA19-9 was 0.897. Comparing serum levels of WASF2, ARF6, SNORA74A, SNORA25, and CA19-9 revealed that levels of WASF2 were the most highly correlated with the risk of pancreatic cancer. The AUCs of WASF2, ARF6, SNORA74A, and SNORA25 in serum from patients in the early stages of pancreatic cancer (stages 0, I, and IIA) were > 0.9, compared with an AUC of 0.93 for the level of CA19-9. The results of this study suggest that WASF2, ARF6, SNORA74A, and SNORA25 may be useful tools for the early detection of pancreatic cancer. Monitoring serum levels of WASF2 mRNA may be particularly useful, as it was the most highly correlated with pancreatic cancer risk.
Identifiants
pubmed: 30358104
doi: 10.1002/1878-0261.12398
pmc: PMC6360365
doi:
Substances chimiques
CA-19-9 Antigen
0
RNA, Messenger
0
RNA, Neoplasm
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
212-227Subventions
Organisme : Grants-in-Aid for Scientific Research
ID : 15K14396
Pays : International
Organisme : Grants-in-Aid for Scientific Research
ID : 16K09397
Pays : International
Organisme : Grants-in-Aid for Scientific Research
ID : 17K09463
Pays : International
Informations de copyright
© 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
J Clin Oncol. 2006 Nov 20;24(33):5313-27
pubmed: 17060676
Nat Rev Immunol. 2002 Aug;2(8):569-79
pubmed: 12154376
World J Surg Oncol. 2013 Sep 04;11:219
pubmed: 24007214
Proteomics. 2009 Nov;9(21):4997-5000
pubmed: 19810033
Pancreat Disord Ther. 2016;6(2):e148
pubmed: 27030812
Oncotarget. 2015 Dec 1;6(38):40575-87
pubmed: 26528758
Bioessays. 2013 Jan;35(1):46-54
pubmed: 23180440
Nat Struct Mol Biol. 2015 Jan;22(1):11-9
pubmed: 25565028
World J Gastroenterol. 2014 Oct 7;20(37):13325-42
pubmed: 25309068
PLoS One. 2010 Jul 26;5(7):e11779
pubmed: 20668672
Gastroenterology. 1999 Dec;117(6):1464-84
pubmed: 10579989
Clin Cancer Res. 2010 Dec 15;16(24):5928-35
pubmed: 20962028
J Exp Clin Cancer Res. 2016 Dec 5;35(1):190
pubmed: 27919290
Biometrics. 1988 Sep;44(3):837-45
pubmed: 3203132
CA Cancer J Clin. 2013 Jan;63(1):11-30
pubmed: 23335087
Nat Genet. 2016 Jan;48(1):53-8
pubmed: 26595770
Cancer Res. 2011 Feb 1;71(3):895-905
pubmed: 21266361
Neuron. 2010 Apr 15;66(1):57-68
pubmed: 20399729
Oncotarget. 2016 Dec 20;7(51):85551-85563
pubmed: 27888803
Pancreatology. 2016 Sep-Oct;16(5):905-16
pubmed: 27453460
Oncotarget. 2017 Mar 7;8(10):17279-17291
pubmed: 27999198
Asian Pac J Cancer Prev. 2014;15(7):2971-7
pubmed: 24815433
Mol Cell. 2008 Nov 21;32(4):519-28
pubmed: 19026782
Trends Cell Biol. 2014 Aug;24(8):472-8
pubmed: 24985940
Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):E968-77
pubmed: 26858453
J Extracell Vesicles. 2015 Aug 28;4:26533
pubmed: 26320937
Mol Cancer. 2016 May 12;15(1):36
pubmed: 27176474
Oncogene. 2012 May 31;31(22):2794-804
pubmed: 21986946
Nature. 2015 Jul 9;523(7559):177-82
pubmed: 26106858
Oncotarget. 2016 Aug 9;7(32):51515-51524
pubmed: 27285987
Oncotarget. 2014 Aug 30;5(16):6832-45
pubmed: 25216519
Neoplasia. 2014 Dec;16(12):1082-93
pubmed: 25499221
Nucleic Acids Res. 2017 Sep 6;45(15):8647-8660
pubmed: 28911119
Oncotarget. 2016 Sep 13;7(37):59173-59188
pubmed: 27385095
Mol Cancer. 2010 Jul 27;9:198
pubmed: 20663213